CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The ALADDIN project aims to revolutionize the discovery of therapeutic antibodies for human cancer. It integrates advanced techniques like artificial intelligence and microfluidics to streamline the process, eliminating the need for animal testing and enhancing preclinical validation efficiency.
Since the approval of the first monoclonal antibody (mAb) 30 years ago, therapeutic mAbs and Ab-derived molecules have come to dominate the biologics market.
Currently, +100 Abs are in clinical use for different diseases, out of which +30 mAb target cancer.
Despite the huge market potential, multiple and complex steps make the therapeutic Ab discovery process long, expensive, laborious, and inefficient.
These steps include target identification, animal immunization, Ab selection and engineering…
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
LABORATORIO IBERICO INTERNACIONAL DE NANOTECNOLOGIA LIN
Portugal, Braga
Type: Research institute
Activity type: Research Organisations
SME: No
THE HEBREW UNIVERSITY OF JERUSALEM
Israel, Jerusalem
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Sweden, Linkoping
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
